Vaping and young adult respiratory health: cohort study findings
Vaping has shifted from a niche cessation aid to a widespread habit among under-25s across Australia, with nicotine-containing devices now the most commonly used tobacco-related product in the 18-to-24 age group. The arrival of disposables, refillable mods and fruit-forward flavours helped propel this trend on campuses in Brisbane, Sydney and Melbourne. Health authorities have watched the rise with concern because the long-term pulmonary effects of inhaled aerosols remain poorly characterised.
Cohort evidence is starting to fill that knowledge gap. Longitudinal research following previously tobacco-naïve young adults has begun documenting measurable changes in lung function, airway reactivity and symptom burden over short follow-up windows, with implications for clinicians, policymakers and families supporting young people who took up the habit believing it was harmless.
Translating findings into clinical guidance sits at the heart of research translation work. Brisbane Diamantina Health Partners, a Queensland collaborative linking universities, hospitals and research institutes, hosts resources connecting evidence to frontline practice. Understanding what the cohort literature actually shows is the first step in shaping better conversations between clinicians and their younger patients.
Rising vaping prevalence among Australian young adults
The Australian Institute of Health and Welfare reports that current e-cigarette use among 18-to-24-year-olds has climbed steeply, with regular users now a meaningful share of the age group. Queensland university surveys suggest experimentation often begins in the first year of tertiary study, frequently in social settings where devices are passed around between mates at parties or in share houses.
The product landscape has changed as well. Early cig-a-likes have given way to high-concentration nicotine salt devices that feel smoother on the throat. Smoother delivery encourages deeper inhalation and longer puff sessions, increasing the dose of aerosolised chemicals reaching the lower airways.
Australian policy has caught up. Since 2024, nicotine vapes can only be lawfully supplied through a pharmacy with a prescription, and the Therapeutic Goods Administration has tightened restrictions on importation, advertising and packaging. Even so, many young adults still access devices through informal channels, including friends, online resellers and convenience stores operating in a grey zone.
What the cohort study tracked
The cohort enrolled several hundred young adults aged 18 to 25 across multiple Australian sites, including Brisbane and adjacent regions. Participants were grouped into exclusive vapers who had never smoked, a never-use comparison group and current smokers, with spirometry, impulse oscillometry and validated symptom questionnaires repeated at regular intervals.
Researchers recorded device type, nicotine concentration, flavour profile and lifetime consumption, using urinary cotinine to verify exposure and saliva tests to rule out recent smoking. This phenotyping matters because lumping all vapers together can mask important differences between occasional low-strength users and those chain-vaping high-concentration disposables throughout the arvo.
The cohort was designed to capture early signals of harm rather than decades-long outcomes, given how recent widespread use is. Participants are being followed for several years, with planned analyses examining whether early lung function changes predict later diagnoses such as asthma, chronic bronchitis or recurrent wheeze.
Key respiratory findings
Exclusive vapers showed measurable reductions in small airway function compared with the never-use group, even after adjusting for asthma history, exercise patterns and air pollution exposure. Impulse oscillometry detected resistance increases at five and twenty hertz that were not always visible on routine spirometry performed in clinic.
Symptom data told a parallel story. Vapers reported higher rates of chronic cough, phlegm and exertional breathlessness, with the heaviest users faring worst. Even participants describing their use as light or social showed early signs of airway irritation, suggesting there may be no completely safe threshold for regular inhalation of flavoured aerosols.
When the analysis examined flavourings, menthol and fruit variants were associated with stronger inflammatory markers in exhaled breath condensate. The cohort authors cautioned that flavouring chemicals, generally regarded as safe for ingestion, have not been tested for chronic inhalation safety. Smaller biopsy substudies have shown epithelial changes resembling, in pattern if not in severity, those seen in traditional smokers.
Local context and policy response
These findings arrive as regulation moves quickly. Queensland Health has backed the prescription-only model and funds Quitline services for young people, including text-based support and outreach through TAFE and university wellbeing services. The Royal Brisbane and Women's Hospital has piloted a youth vaping cessation clinic, reflecting the clinical innovation that translation networks like Brisbane Diamantina actively champion.
Community organisations across the Sunshine State have leaned into prevention as well. School-based programs in Ipswich, Logan and Brisbane's western suburbs have updated curriculum materials on respiratory risks, and several local councils have restricted the proximity of vape retailers to schools through planning controls. The message from public health leaders is consistent: the cohort evidence strengthens the case for protecting young lungs during a critical developmental window.
On the research translation side, Queensland-based investigators are using these findings to inform shared decision-making tools that GPs can use during consultations with patients who vape. This work builds on broader activity at Brisbane Diamantina examining how evidence enters routine care. For comparison, researchers studying culturally diverse communities have explored group-based diabetes care, demonstrating how peer-supported clinical formats can shift health behaviours in ways that one-on-one consultations sometimes cannot.
Practical recommendations for clinicians and communities
- Ask every young adult patient about vaping during routine respiratory and cardiovascular reviews, framing the question neutrally and without assumptions about prior smoking history.
- Use impulse oscillometry or repeat spirometry where available, particularly for patients reporting cough, wheeze or reduced exercise tolerance, as standard tests can miss early small-airway changes.
- Support patients wanting to quit with behavioural counselling, PBS-subsidised nicotine replacement therapy and pharmacy-led cessation support where appropriate.
- Engage parents, schools and community groups with current evidence, recognising that misinformation about vaping safety remains widespread among older relatives as well as peers.
The cohort evidence makes one message clear: e-cigarette use is not risk-free, particularly for young adults whose lungs are still developing. Clinicians across Queensland and beyond can act today by asking about vaping, documenting respiratory symptoms carefully and connecting patients with cessation support that fits their circumstances. Researchers can build on these findings by embedding respiratory endpoints into broader chronic disease and lifestyle studies. Stay across new evidence and translation activities shaping respiratory care through Brisbane Diamantina Health Partners.
